India's Jubilant Ingrevia rises as Kotak sees growth outweighing contract risks
BUZZ-India's Jubilant Ingrevia rises as Kotak sees growth outweighing contract risks ** Chemicals maker Jubilant Ingrevia JUBN.NS shares rise 3.7% to 640.55 rupees
** Kotak Institutional Equities reiterates positive stance on co amid the correction in the stock
** Says it continues to expect JUBN to deliver sharp earnings growth in FY27 and beyond, underpinned by co's order book and improved results from chemical intermediaries
** "In our view, the biggest overhang on the stock is the concern around possible cancellation of the FMC contract given that JUBN's pricing in significantly higher than that currently offered by Chinese competition," - Kotak
** Brokerage retains "Buy" rating on stock with a revised fair value of 1,010 rupees from 960 rupees previously, representing a 63.5% upside to the stock's last close
** YTD, JUBN down 9.2%
(Reporting by Abhinav Parmar in Bengaluru)
Recent news on Jubilant Ingrevia
See all newsBrief: Jubilant Ingrevia Says Board Approves Acquisition Of 40% Strategic Equity Stake In Zettaone Through Subsidiary
India's Jubilant Ingrevia rises as Kotak sees growth outweighing contract risks
Brief: Jubilant Ingrevia To Buy 40% Stake In Zettaone Technologies India For 1.89 Billion Rupees
Brief: Jubilant Ingrevia June-Quarter Consol Net Profit 1.06 Billion Rupees
Brief: Jubilant Ingrevia March-Quarter Consol Net Profit 864.4 Million Rupees